Xilio Therapeutics (XLO) Current Assets (2020 - 2026)

Xilio Therapeutics has disclosed Current Assets across 7 years of filings, most recently posting $145.5 million for Q2 2026.

• In Q2 2026, Current Assets rose 17.58% year-over-year to $145.5 million; the TTM figure through Jun 2026 stood at $145.5 million (up 17.58% YoY), while the FY2025 annual figure was $145.0 million, up 140.77% from the prior year.
• Current Assets came in at $145.5 million for Q2 2026 at Xilio Therapeutics, down from $154.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $181.1 million in Q1 2022 to a low of $48.1 million in Q4 2023.
• Average Current Assets over 5 years is $108.6 million, with a median of $110.3 million recorded in 2023.
• Year-over-year, Current Assets plunged 61.34% in 2023 and surged 140.77% in 2025.
• Over 5 years, Current Assets stood at $124.5 million in 2022, then sank by 61.34% to $48.1 million in 2023, then rose by 25.16% to $60.2 million in 2024, then surged by 140.77% to $145.0 million in 2025, then climbed by 0.3% to $145.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $145.5 million in Q2 2026, $154.2 million in Q1 2026, and $145.0 million in Q4 2025.